12.56 USD
▲-0.09+6.35%
2026-08-03
市值
$719.19M
市盈率
—
EPS
-0.79
股息率
—
52 周区间
1.54 – 14.42
成交量
1.03M
Beta
0.09
目标价
20.85
52W 低 1.5452W 高 14.42
价格走势
公司简介
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ...